Epidermolysis Bullosa Dystrophica
1
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Abeona TherapeuticsCLEVELAND, OH
1 program1
LZRSE-Col7A1 Engineered Autologous Epidermal SheetsPhase 1/21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Abeona TherapeuticsLZRSE-Col7A1 Engineered Autologous Epidermal Sheets
Tissue RepairCACIPLIQ20
Clinical Trials (2)
Total enrollment: 28 patients across 2 trials
Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa
Start: Oct 2010Est. completion: Mar 202212 patients
Phase 1/2Completed
CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa
Start: Jan 2024Est. completion: Sep 202416 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.